Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials

被引：19
|
作者：
Roshanov, Pavel S. [1 ]
Dennis, Brittany B. [2 ]
机构：
[1] Univ Western Ontario, Schulich Sch Med & Dent, London, ON N6G 2M1, Canada
[2] St Josephs Healthcare Hamilton, Peter Boris Ctr Addict Res, Hamilton, ON L8N 4A6, Canada
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2015年 / 110卷 / 03期
关键词：
Acute pancreatitis; Gliptins; Incretins; DDP4; inhibitors; Safety; CARDIOVASCULAR OUTCOMES;
D O I：
10.1016/j.diabres.2015.10.014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Previous studies have offered weak and conflicting evidence regarding the impact of incretin-based oral antihyperglycemic agents on risk of acute pancreatitis. This meta-analysis of three recent mega-trials found an 82% increase in the odds of acute pancreatitis with the use of these agents compared to usual care (95% CI, 1.17-2.82). (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：E13 / E17
页数：5
相关论文
共 50 条
  • [1] Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
    Giorda, Carlo B.
    Sacerdote, Carlotta
    Nada, Elisa
    Marafetti, Lisa
    Baldi, Ileana
    Gnavi, Roberto
    ENDOCRINE, 2015, 48 (02) : 461 - 471
  • [2] Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
    Wang, Haining
    Liu, Ye
    Tian, Qing
    Yang, Jin
    Lu, Ran
    Zhan, Siyan
    Haukka, Jari
    Hong, Tianpei
    DIABETES OBESITY & METABOLISM, 2018, 20 (04) : 910 - 920
  • [3] Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
    Carlo B. Giorda
    Carlotta Sacerdote
    Elisa Nada
    Lisa Marafetti
    Ileana Baldi
    Roberto Gnavi
    Endocrine, 2015, 48 : 461 - 471
  • [4] Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials
    Singh, Awadhesh Kumar
    Gangopadhyay, Kalyan Kumar
    Singh, Ritu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (04) : 461 - 468
  • [5] Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials
    Wang, Tiansheng
    Wang, Fei
    Zhou, Junwen
    Tang, Huilin
    Giovenale, Sharon
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (08) : 843 - 857
  • [6] Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials
    Abd El Aziz, Mirna
    Cahyadi, Oscar
    Meier, Juris J.
    Schmidt, Wolfgang E.
    Nauck, Michael A.
    DIABETES OBESITY & METABOLISM, 2020, 22 (04) : 699 - 704
  • [7] Risk of pancreatitis in patients treated with incretin-based therapies
    Meier, Juris J.
    Nauck, Michael A.
    DIABETOLOGIA, 2014, 57 (07) : 1320 - 1324
  • [8] Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
    Liu, Lili
    Shao, Zhuo
    Xia, Ying
    Qin, Jiabi
    Xiao, Yang
    Zhou, Zhiguang
    Mei, Zubing
    ENDOCRINE CONNECTIONS, 2019, 8 (03) : 277 - 288
  • [9] Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials
    Mahmoud, Ahmed N.
    Saad, Marwan
    Mansoor, Hend
    Elgendy, Akram Y.
    Barakat, Amr F.
    Abuzaid, Ahmed
    Mentias, Amgad
    Elgendy, Islam Y.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 230 : 324 - 326
  • [10] Glutamine supplementation in acute pancreatitis: A meta-analysis of randomized controlled trials
    Asrani, Varsha
    Chang, Wai Keat
    Dong, Zhiyong
    Hardy, Gil
    Windsor, John A.
    Petrov, Maxim S.
    PANCREATOLOGY, 2013, 13 (05) : 468 - 474
12345